Screener
Immunovant, Inc. IMVT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Net loss per common share — basic and diluted | $(2.77) | $(2.73) | $(1.88) |
| Weighted average common shares outstanding — basic and diluted | 182,421,233 | 151,573,553 | 138,100,577 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s business segments — net loss?
- Immunovant, Inc. (IMVT) reported business segments — net loss of $147.86M in Q1 2026.
- How has Immunovant, Inc.'s business segments — net loss changed year-over-year?
- Immunovant, Inc.'s business segments — net loss increased by 38.9% year-over-year, from $106.45M to $147.86M.
- What is the long-term trend for Immunovant, Inc.'s business segments — net loss?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — net loss has grown at a 33.8% compound annual growth rate (CAGR), from $210.96M to $505.61M.
- What does business segments — net loss mean?
- The total financial loss generated by the reportable segment after accounting for all operating expenses and non-operating items. For clinical-stage companies, this reflects the burn rate required to fund research and development activities before commercialization. It is a critical metric for evaluating the company's financial sustainability and capital runway.
Ask your AI about Immunovant, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude